<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article127</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/PARAGON-HF" style="display:block; margin-bottom:10px;">PARAGON-HF Original</a></li>
<h2><strong>PARAGON-HF</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Sacubitril-Valsartan in Heart Failure with Preserved Ejection Fraction". The New England Journal of Medicine. 2019.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does sacubitril-valsartan reduce hospitalizations for heart failure and cardiovascular death in patients with heart failure with preserved ejection fraction?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Sacubitril-valsartan did not lead to a statistically significant reduction in total hospitalizations for heart failure and cardiovascular death compared to valsartan alone in patients with heart failure with preserved ejection fraction.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
<hr/><br/>
<h2><strong>Guidelines have not yet reflected the results of this trial as of the knowledge cutoff date.</strong></h2><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, parallel-group, randomized, active-comparator trial.<br/>
- Patients were assigned to sacubitril-valsartan (n=2419; target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (n=2403; target dose, 160 mg twice daily).<br/>
- The median follow-up duration was 35 months.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Enrolled 4822 patients with NYHA class II-IV heart failure, ejection fraction â‰¥ 45%, elevated levels of natriuretic peptides, and structural heart disease.<br/>
- Median age: 73 years, 52% female, median ejection fraction 57%.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- After a single-blind run-in period with half-target doses, participants who tolerated both drugs without issues were randomized to either sacubitril-valsartan or valsartan.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary outcome: Composite of total hospitalizations for heart failure and death from cardiovascular causes.<br/>
- Secondary outcomes: NYHA class change, worsening renal function, and change in KCCQ clinical summary score.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
The trial did not meet its primary endpoint, with a primary event rate ratio of 0.87 (95% CI, 0.75-1.01; P=0.06) favoring sacubitril-valsartan. Subgroup analyses suggested potential benefit in women and patients with lower ejection fractions. Secondary outcomes showed some improvements in NYHA class and fewer cases of worsening renal function with sacubitril-valsartan versus valsartan.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The trial narrowly missed statistical significance, and multiple secondary analyses suggested potential benefits, generating debate about the clinical application of the findings.<br/>
- Subgroup analyses were not prespecified primary endpoints, limiting the conclusiveness of results for specific patient demographics.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The trial was funded by Novartis.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
